AMA awards unique CPT code for Cylex' ImmuKnow assay

Cylex Incorporated® announced today that the American Medical Association (AMA) CPT Editorial Panel approved the creation of new CPT coding based on the uniqueness, clinical value and widespread use of ImmuKnow, and the fact that existing CPT codes insufficiently captured all steps and costs of testing.

In an effort to keep customers informed of these changes, the following new information is now available:

  • ImmuKnow is mapped to CPT Code: 86352, "Cellular function assay involving stimulation (e.g., mitogen or antigen) and detection of a biomarker (e.g., ATP)"

"We are very pleased by the decision of the AMA to recognize the value of ImmuKnow as a biomarker that provides valuable insight for individualized patient management by establishing a unique CPT code," said President, CEO and Chairman Brad L. Stewart. "We look forward to assisting clinicians with continuing to expand the implementation of ImmuKnow as standard of care in more effectively managing their patients' immunosuppression."

ImmuKnow is a biomarker of immune function that complements immunomodulatory therapy and helps physicians and other healthcare professionals more effectively manage immunosuppression in posttransplant patients, thereby reducing the risks of infection and rejection by:

  • Providing a global marker of immune function and response to immunosuppression at the cellular level
  • Detecting changes in CD4 cell ATP production
  • Helping to define a range of stable immune function for each patient
  • Providing critical, actionable information on an ongoing, individual basis when used longitudinally (in combination with other routine monitoring tests)

ImmuKnow is the FDA-cleared assay that tracks changes in global immune function over time.

SOURCE Cylex, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research demonstrates a bat species' resistance to cancer, pinpoints key genes